Pictet新興市場崛起經濟體主動型ETF RISE 深 滬
已收盤 11-06 16:00:00 美东时间
17.7378
+0.093
+0.52%
華盛通- 最 高17.7378
- 今 開17.71
- 成交量 589股
- 最 低 17.67
- 昨 收 17.6453
- 總市值 2039.85万
- 52周最高 19.435
- 市盈率 靜 --
- 換手率 0.05%
- 52周最低 17.2664
- 委 比 0.00%
- 總股本 115.00万
- 歷史最高 19.435
- 量 比 0.26
- 振 幅 0.38%
- 歷史最低 17.2719
- 每 手 1
- 風險率 0.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多SenesTech Expands E-Commerce Reach Through Walmart Fulfillment Services
SenesTech, Inc. announced that its Evolve® rodent control products are now available through Walmart Fulfillment Services (WFS), enhancing its e-commerce capabilities. This partnership improves delivery speed, convenience, and nationwide reach, while reducing fulfillment costs and supporting business growth. WFS integration has already boosted sales on Walmart.com, aligning with SenesTech's strategy to expand e-commerce and accessibility for sust...
11-03 20:00
BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026
BioVie Inc. has been invited to present late-breaking data on its drug Bezisterim at the 4th Long COVID International Conference. The presentation will highlight findings from the Phase 2 ADDRESS-LC trial, showing significant improvements in fatigue, post-exertional malaise, and cognition in high-symptom-burden patients with Long COVID. Bezisterim, which targets neuroinflammation, has demonstrated potential in reducing symptoms linked to persiste...
11-02 14:00
Sandstrom Partners Hired As Strategic Advisor on Marketing and Branding
SenesTech, a leader in rodent control, has enlisted Sandstrom Partners as a strategic advisor to boost e-commerce and B2B sales growth. Sandstrom, renowned for brand development, will provide services including market research, brand strategy, and digital design to enhance SenesTech's communication with customers. SenesTech's Evolve and ContraPest products, which use non-lethal methods to control rodent populations, have shown significant success...
10-28 12:00
BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
BioVie Inc. announced that two abstracts from its ADDRESS-LC Phase 2 trial for Long COVID and SUNRISE-PD Phase 2 trial for Parkinson’s Disease have been accepted for presentation at ANA2026 in San Diego, October 17-20, 2026. The studies will be presented as posters. Bezisterim (NE3107), the company’s investigational drug, targets neuroinflammation and insulin resistance, showing potential benefits in reducing inflammation and improving symptoms i...
10-14 12:00
